Status:
COMPLETED
HIV Risk Reduction and Drug Abuse Treatment in Malaysia
Lead Sponsor:
Yale University
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Opiate Dependence
Eligibility:
MALE
18-65 years
Phase:
PHASE2
Brief Summary
A randomized clinical trial comparing drug abuse and HIV risk reduction counseling (DC-HIV) alone, DC-HIV combined with naltrexone maintenance, and DC-HIV combined with buprenorphine maintenance for t...
Detailed Description
Combining drug abuse and HIV risk reduction counseling with opioid agonist maintenance treatment (OMT) or antagonist maintenance treatment with naltrexone (NMT) is effective for reducing illicit drug ...
Eligibility Criteria
Inclusion
- Opioid dependence
Exclusion
- Dependence on alcohol, benzodiazepines or sedatives
- Suicide or homicide risk
- Psychotic disorder or major depression
- Inability to read or understand the protocol or assessment questions
- Life-threatening or unstable medical problems
- Greater than 3 times normal liver enzymes (AST, GGT)
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
End Date :
August 1 2007
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT00383045
Start Date
April 1 2003
End Date
August 1 2007
Last Update
March 31 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale University School of Medicine
New Haven, Connecticut, United States, 06519
2
Substance Abuse Research Center
Muar town, Johor, Malaysia